Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
ARCH Venture Partners has successfully raised $3 billion for its 13th fund, marking one of the largest funds in the biotech industry. The venture capital firm plans to use the capital to support early-stage biotech companies and pursue innovative scientific advancements. This new fund follows the $2.975 billion Fund XII announced previously. ARCH Venture Partners, led by Bob, Kristina, Paul, and Carol, is known for its contrarian investment strategy and aims to leverage AI and data-driven insights into biology to drive the future of healthcare.
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science https://t.co/A1IczIwlZT by @gwendolynawu
Arch Venture Partners, the Sequoia/Founders Fund of biotech, just raised $3B+ for their 13th fund. @rtnarch, Head of Arch, specifically calls out how AI and data-driven insights into biology will be key for the future of healthcare. Incredibly important work.
ARCH Venture Partners has raised $3 billion for a new fund — one of the largest in the biotech industry, and one the VC firm will deploy using its contrarian investment strategy. https://t.co/bys1E0kJlm
